Valneva Se (VALN)

Operator: Good day, and thank you for standing by. Valneva presents its First Quarter 2026 Financial Results. [Operator Instructions] Please be advised that today's conference is being recorded.

Valneva SE (NASDAQ:VALN) is one of the most undervalued biotech stocks to buy right now. Guggenheim cut the price target on Valneva SE (NASDAQ:VALN) to $11 from $13 on April 16, reiterating a Buy rating...

On April 13, Tom Lee, Fundstrat's head of research, appeared on CNBC’s 'Power Lunch' to talk about his outlook on equities, what to expect in a wartime economy, and more.

Oversold stocks are getting a fresh look in 2026, but not simply because they are down.

Operator: Good day, and thank you for standing by. Welcome to the Valneva 9 Months 2025 Financial Results Conference Call and Webcast.

Joshua Drumm: Thank you, operator. Hello, and thank you for joining us to discuss Valneva's first half 2025 results and corporate update. It's my pleasure to welcome you today.

Joshua Drumm: Thank you. Hello, and thank you for joining us to discuss Valneva's first quarter 2025 results and corporate update. It's my pleasure to welcome you today.

On March 29, T. Rowe Price portfolio manager Tony Wang appeared on CNBC’s 'Closing Bell Overtime' to discuss the current volatility in the tech sector, especially the NASDAQ.

Joshua Drumm: Thank you. Hello, and thank you for joining us to discuss Valneva’s Full Year 2024 Results and Corporate Update. It’s my pleasure to welcome you today.